Phase II
VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.
Checkpoint inhibitors are only effective against inflamed tumors, called ‘hot’ tumors. Unfortunately, most tumors are ‘cold’ (not inflamed) and hide from the immune system by appearing to be too similar to normal cells.
InflaRx N.V. today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).
Theranexus announces today that it has recruited the last patient in its Phase II trial, entitled “Tolerance and Efficacy of THN102 on Sleepiness in Narcoleptic Patients”.
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension
At the 11th Clinical Trials in Alzheimer’s Disease Conference
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018
Cristal Therapeutic announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.
Initial data from the first cohort expected in first half of 2019
The United Kingdom is calling for greater clinical trial transparency after a government committee released a report that indicates that data from about half of all clinical trials in that country are not published, raising concerns over research integrity and risks to human health.
PRESS RELEASES